Golidocitinib is a JAK/STAT signaling pathway inhibitor, mainly used for the treatment of relapsed or refractory T-cell lymphoma. Its common adverse reactions include hematological abnormalities (such as thrombocytopenia and neutropenia), elevated infection risk, gastrointestinal reactions (nausea, diarrhea), etc. Specific manifestations vary from person to person. Strict medical guidance and regular monitoring of relevant indicators are required during medication.
Ⅰ. Common Adverse Reactions
1. Hematological Abnormalities
Thrombocytopenia: May lead to bleeding tendencies (e.g., epistaxis, ecchymosis). Regular complete blood count (CBC) monitoring is required.
Neutropenia: Increases the risk of infection; drug administration may need to be suspended or the dosage adjusted in severe cases.
Anemia: Manifests as fatigue and dizziness. Supportive symptomatic treatment is necessary when required.
2. Elevated Infection Risk
Immunosuppression may induce bacterial, viral or fungal infections, such as respiratory tract infections and herpes zoster. Immediate medical attention is needed if symptoms like fever or cough occur.
3. Gastrointestinal Reactions
Common reactions include nausea, vomiting and diarrhea, which are generally mild to moderate and can be relieved through dietary adjustment or medication.
Ⅱ. Severe Adverse Reactions Requiring Vigilance
1. Severe Infections
Including pneumonia, sepsis, etc. The drug must be discontinued immediately, followed by active anti-infective treatment.
2. Hepatic Dysfunction
Transaminase elevation may occur in some patients. Regular liver function monitoring is required, and hepatoprotective treatment should be given when necessary.
3. Allergic Reactions
Rare but may present as rash, pruritus or dyspnea. The drug must be stopped immediately and medical treatment sought promptly.
Ⅲ. Precautions for Medication
Regular Monitoring: Complete blood count, liver and renal function should be examined every 1–2 weeks during treatment, and the dosage adjusted according to the test results.
Avoid Self-Medication: Concomitant use of other immunosuppressants or live vaccines is prohibited without medical advice.
Special Populations: Pregnant women, lactating females and patients with hepatic or renal insufficiency need careful risk assessment before use.
Golidocitinib is a prescription drug. It must be evaluated by a professional physician prior to use. Patients should contact their medical team promptly if any abnormal symptoms (e.g., persistent fever, severe fatigue) develop during treatment.
